Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy

Pragya Srivastava, Benjamin E. Paluch, Junko Matsuzaki, Smitha R. James, Golda Collamat-Lai, Nadja Blagitko-Dorfs, Laurie Ann Ford, Rafeh Naqash, Michael Lübbert, Adam R. Karpf, Michael J. Nemeth, Elizabeth A. Griffiths

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Cancer testis antigens (CTAs) are promising cancer associated antigens in solid tumors, but in acute myeloid leukemia, dense promoter methylation silences their expression. Leukemia cell lines exposed to HMAs induce expression of CTAs. We hypothesized that AML patients treated with standard of care decitabine (20mg/m2 per day for 10 days) would demonstrate induced expression of CTAs. Peripheral blood blasts serially isolated from AML patients treated with decitabine were evaluated for CTA gene expression and demethylation. Induction of NY-ESO-1 and MAGEA3/A6, were observed following decitabine. Re-expression of NY-ESO-1 and MAGEA3/A6 was associated with both promoter specific and global (LINE-1) hypomethylation. NY-ESO-1 and MAGEA3/A6 mRNA levels were increased irrespective of clinical response, suggesting that these antigens might be applicable even in patients who are not responsive to HMA therapy. Circulating blasts harvested after decitabine demonstrate induced NY-ESO-1 expression sufficient to activate NY-ESO-1 specific CD8+ T-cells. Induction of CTA expression sufficient for recognition by T-cells occurs in AML patients receiving decitabine. Vaccination against NY-ESO-1 in this patient population is feasible.

Original languageEnglish (US)
Pages (from-to)12840-12856
Number of pages17
JournalOncotarget
Volume7
Issue number11
DOIs
StatePublished - Mar 15 2016

Keywords

  • Acute myeloid leukemia
  • Cancer testis antigen
  • Decitabine
  • Immunotherapy
  • Ny-ESO-1

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy'. Together they form a unique fingerprint.

  • Cite this

    Srivastava, P., Paluch, B. E., Matsuzaki, J., James, S. R., Collamat-Lai, G., Blagitko-Dorfs, N., Ford, L. A., Naqash, R., Lübbert, M., Karpf, A. R., Nemeth, M. J., & Griffiths, E. A. (2016). Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget, 7(11), 12840-12856. https://doi.org/10.18632/oncotarget.7326